The neuroprotective role of erythropoietin in the management of acute ischaemic stroke: From bench to bedside

Acta Neurologica Scandinavica

Volumn 118, Issue 6, 2008, Pages 362-366

  Ntaios, G ^a,b   Savopoulos, C ^a   Chatzinikolaou, A ^a   Hatzitolios, A I ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Asialic erythropoietin; Carbamylated erythropoietin; Erythropoietin; Neuroprotection; Stroke

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

BARTHEL INDEX; BRAIN TISSUE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIFFUSION WEIGHTED IMAGING; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROPROTECTION; NONHUMAN; RANKIN SCALE; REVIEW;

ACUTE DISEASE; ANIMALS; BRAIN; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; ERYTHROPOIETIN; HUMANS; NEUROPROTECTIVE AGENTS; RECOMBINANT PROTEINS; STROKE; TREATMENT OUTCOME;

EID: 55949111418     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2008.01039.x     Document Type: Review

References (39)

1. Siren A, Knerlich F, Poser W et al. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol 2001 101 : 271 6.
2. Juul SE, Anderson DK, Li Y et al. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998 43 : 40 9.
3. Nagai A, Nakagawa E, Choi HB et al. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 2001 60 : 386 92.
4. Marti HH, Wenger RH, Rivas LA et al. Erythropoietin gene expression in human, monkey and human brain. Eur J Neurosci 1996 8 : 666 76.
5. Brines ML, Ghezzi P, Keenan S et al. Erythropoietin crosses the bloodbrain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000 97 : 10526 31.
6. Bernaudin M, Marti HH, Roussel S et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999 19 : 643 51.
7. Yamaji R, Okada T, Moriya M et al. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 1996 239 : 494 500.
8. Brines M. What evidence supports use of erythropoietin as a novel neurotherapeutic? Oncology 2002 16 : 79 89.
9. Sadamoto Y, Igase K, Sakanaka M et al. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 1998 253 : 26 32.
10. Sakanaka M, Wen TC, Matsuda S et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998 95 : 4635 40.
11. Faure S, Oudart N, Javellaud J et al. Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil. J Hypertens 2006 24 : 2255 61.
12. Yu Y, Xu Q, Zhang Q et al. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 2005 387 : 5 10.
13. Bailey D, Robach P, Thomsen J et al. Erythropoietin depletes iron stores: antioxidant neuroprotection for ischemic stroke? Stroke 2006 37 : 2453.
14. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992 59 : 1609 23.
15. Van Der A DL, Grobbee DE, Roest M et al. Serum ferritin is a risk factor for stroke in postmenopausal women. Stroke 2005 36 : 1637 41.
16. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988 1 : 623 34.
17. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 1990 13 : 171 82.
18. Morishita E, Masuda S, Nagao M et al. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997 76 : 105 16.
19. Miller BA, Barber DL, Bell LL et al. Identification of the eryhtropoietin receptor domain required for calcium channel activation. J Biol Chem 1999 274 : 20465 72.
20. Cavdar C, Camsari T, Semin I et al. Lipid peroxidation and antioxidant activity in chronic haemodialysis patients treated with recombinant human erythropoietin. Scand J Urol Nephrol 1997 31 : 371 5.
21. Chattopadhyay A, Choudhury TD, Bandyopadhyay D et al. Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem Pharmacol 2000 59 : 419 25.
22. Gorio A, Gokmen N, Erbayraktar S et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 2002 99 : 9450 55.
23. Agnello D, Bigini P, Villa P et al. Erythropoietin exerts anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 2002 952 : 128 34.
24. Anagnostou A, Lee ES, Kesseimian N et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990 87 : 5978.
25. Anagnostou A, Liu Z, Steiner M et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994 91 : 3974.
26. Ribatti D, Presta M, Vacca A et al. Human erythropoietin induces a proangiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999 93 : 2627 36.
27. Ehrenreich H, Hasselblatt M, Dembowski C et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002 8 : 495 505.
28. Hasselblatt M, Ehrenreich H, Siren AL. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J Neurosurg Anesthesiol 2006 18 : 132 8.
29. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992 72 : 449 89.
30. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alpha in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005 23 : 5960 72.
31. Konstantinopoulos P, Karamouzis M, Papavassiliou A. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin. Biochim Biophys Acta 2007 1776 : 1 9.
32. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007 25 : 1027 32.
33. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Canc Inst 2006 98 : 708 14.
34. http://www.fda.gov/cder/drug/infopage/RHE/default.htm. Accessed November 6, 2007 P, Van Beek J, Larsen AK et al. Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab 2007 27 : 552 63.
35. Mahmood A, Lu D, Qu C et al. Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin. J Neurosurg 2007 107 : 392 7.
36. Wang Y, Zhang Z, Rhodes K et al. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br J Pharmacol 2007 151 : 1377 84.
37. King VR, Averill SA, Hewazy D et al. Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat. Eur J Neurosci 2007 26 : 90 100.
38. Erbayraktar S, Grasso G, Sfacteria A et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003 100 : 6741 6.
39. Grasso G, Sfacteria A, Erbayraktar S et al. Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative. J Neurosurg Spine 2006 4 : 310 8.